Cognition-Enhancing Properties of Dimebon in a Rat Novel Object Recognition Task Are Unlikely to Be Associated with Acetylcholinesterase Inhibition or N-Methyl-d-aspartate Receptor Antagonism
Authors:
- Jacqueline A. GibbonsJGJacqueline A. Gibbons
- Sebastián BernalesSBSebastián Bernales
- Iván E. AlfaroIAIván E. Alfaro
- Christophe Drieu La RochelleCRChristophe Drieu La Rochelle
- Thomas CremersTCThomas Cremers
- C. Anthony AltarCAC. Anthony Altar
- Robert WronskiRWRobert Wronski
- Birgit Hutter-PaierBHBirgit Hutter-Paier
- Andrew A. ProtterAPAndrew A. Protter
Open Access
- 1 June 2010
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 333 (3) , 748-757
Abstract
Dimebon (dimebolin) treatment enhances cognition in patients with Alzheimer's disease (AD) or Huntington's disease. Although Dimebon was originally thought to improve cognition and memory through inhibition of acetylcholinesterase (AChE) and the N-methyl-d-aspartate (NMDA) receptor, the low in vitro affinity for these targets suggests that these mechanisms may not contribute to its clinical effects. To test this hypothesis, we assessed whether Dimebon enhances cognition in rats and if such an action is related to either mechanism or additional candidate mechanisms. Acute oral administration of Dimebon to rats (0.05, 0.5, and 5 mg/kg) enhanced cognition in a novel object recognition task and produced Dimebon brain concentrations of 1.7 ± 0.43, 14 ± 5.1, and 172 ± 94 nM, respectively. At these concentrations, Dimebon did not alter the activity of recombinant human or rat brain AChE. Unlike the AChE inhibitors donepezil and galantamine, Dimebon did not change acetylcholine levels in the hippocampus or prefrontal cortex of freely moving rats. Dimebon displays affinity for the NMDA receptor (Ki = 105 ± 18 μM) that is considerably higher than brain concentrations associated with cognition enhancement in the novel object recognition task and 200-fold weaker than that of memantine (Ki = 0.54 ± 0.05 μM). Dimebon did not block NMDA-induced calcium influx in primary neuronal cells (IC50 > 50 μM), consistent with a lack of significant effect on this pathway. The cognition-enhancing effects of Dimebon are unlikely to be mediated by AChE inhibition or NMDA receptor antagonism, and its mechanism of action appears to be distinct from currently approved medications for AD.Keywords
This publication has 44 references indexed in Scilit:
- The Alzheimer's disease mitochondrial cascade hypothesis: An updateExperimental Neurology, 2009
- Mitochondrial Approaches for NeuroprotectionAnnals of the New York Academy of Sciences, 2008
- Mitochondria in Neuroplasticity and Neurological DisordersNeuron, 2008
- Evaluation of Dimebon in cellular model of Huntington's diseaseMolecular Neurodegeneration, 2008
- Histamine H1-receptor blockade in humans affects psychomotor performance but not memoryJournal of Psychopharmacology, 2008
- Comparison of single vs. multiple administrations of the AMPA receptors modulator S 18986 in the object recognition task in ratsFundamental & Clinical Pharmacology, 2007
- The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodentsNeuroscience & Biobehavioral Reviews, 2007
- Comparison of the central nervous system effects produce by six H1‐receptor antagonistsClinical & Experimental Allergy, 1996
- Genomic Cloning, Heterologous Expression and Pharmacological Characterization of a Human Histamine H1 ReceptorBiochemical and Biophysical Research Communications, 1993
- Differentiation of [3H]phencyclidine and ( + )‐[3H]SKF‐10,047 binding sites in rat cerebral cortexFEBS Letters, 1985